Only a handful of interventions are known to prevent the progression of chronic kidney disease (CKD) and the need for kidney replacement therapy. This exclusive list previously only featured angiotensin-converting enzyme inhibitors and angiotensin receptor blockers but recently was expanded to include sodium/glucose cotransporter 2 (SGLT2) inhibitors. These medications also reduce the risk of cardiovascular (CV) events in patients with kidney disease. Despite current, effective treatments, many patients will continue to face kidney failure and an excess of CV events, and the need for additional therapies remains.